In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Teleflex Incorporated is one of them. Teleflex Incorporated (NYSE:TFX) tops our list for being one of the cheap healthcare stocks. It is a global medical technology company and specializes in critical care and surgical devices across hospital and ambulatory settings, including vascular access, interventional urology, respiratory and anesthesia devices, and surgical tools. The company focuses on improving patient outcom ...

The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting StentsWAYNE, Pa., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the enrollment of the first patient in the DUBSTENT DIABETES trial. The randomized, investigator-initiated clinical study will evaluate a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes mellitus. The DUBSTENT DIABETES trial wi ...

Group 1 - The event is the Morgan Stanley Global Healthcare Conference, specifically on Day 2 [1] - Patrick Wood, MD of Equity Research, is leading the presentation [1] - Liam, the CEO of Teleflex, is participating in the conference [2]

Teleflex (NYSE:TFX) FY Conference September 09, 2025 03:20 PM ET Company ParticipantsPatrick Wood - Managing DirectorLiam Kelly - Chairman, President & CEOPatrick WoodK. Let's kick it off. Thanks so much, everyone. Day two, Morgan Stanley Global Healthcare Conference. Patrick, I'm obviously on the MedTech team.I have no idea where the where disclosures thing goes, but it's morgansmiley.com/researchdisclosures. Given I've read that out about 20 times now today, so, I'm sure you can all go there and have a re ...

Industry Overview - The Medical Instruments industry is experiencing a significant transformation due to the integration of generative AI (genAI), which is reshaping diagnostics, patient monitoring, and intervention workflows [1][4] - The FDA is implementing a Total Product Lifecycle (TPLC) oversight framework to enhance safety, transparency, and data integrity in the industry [1] Market Trends - The global AI in healthcare market is projected to grow at a CAGR of 38.5% from 2024 to 2030, despite facing geopolitical challenges such as tariffs and supply chain issues [2] - The generative AI market in healthcare was valued at $1.8 billion in 2023 and is expected to grow at a CAGR of 33.2% from 2024 to 2032 [4] - The diagnostics market is anticipated to grow at a CAGR of 24.6% by 2034, driven by advancements in AI applications [4] M&A Activity - The medical instruments sector is witnessing a surge in merger and acquisition (M&A) activity, with 305 transactions announced in 2024, totaling over $63.1 billion, a significant increase from 134 deals in 2023 [5] - Notable M&A transactions include UnitedHealth Group's $3.3 billion acquisition of Amedisys and Stryker's $4.9 billion purchase of Inari Medical [5] Financial Performance - The Zacks Medical Instruments industry has underperformed the S&P 500, declining 15.4% compared to the broader sector's decline of 17.4% [10] - The industry is currently trading at a forward P/E of 28.46X, higher than the broader industry's 19.32X and the S&P 500's 22.80X [12] Company Highlights - **Teleflex**: Expected 2025 sales of $3.33 billion, a 9.3% increase from 2024, with EPS projected at $14.06, indicating a 0.4% rise [18] - **Integer Holdings**: Anticipated 2025 sales of $1.87 billion, a 7.8% increase from 2024, with EPS expected to rise by 20.4% to $6.38 [22] - **Inogen**: Projected 2025 sales of $355.2 million, a 5.8% increase from 2024, with EPS expected to improve by 37.5% to a loss of 95 cents [26]

Core Viewpoint - The article emphasizes the importance of value investing and highlights Teleflex (TFX) as a strong value stock based on various valuation metrics and its earnings outlook [2][3][8]. Valuation Metrics - Teleflex has a PEG ratio of 1.69, which is lower than the industry average of 2.35, indicating potential undervaluation [4]. - The P/B ratio for Teleflex is 1.33, significantly lower than the industry average of 3.67, suggesting an attractive valuation [5]. - Teleflex's P/S ratio stands at 1.88, compared to the industry's average of 2.73, reinforcing its undervalued status [6]. - The P/CF ratio for Teleflex is 7.96, well below the industry average of 21.07, indicating a solid cash outlook and potential undervaluation [7]. Investment Outlook - The combination of Teleflex's strong valuation metrics and positive earnings outlook positions it as an impressive value stock in the current market [8].

Company Overview - Teleflex Incorporated is a global provider of medical technologies focused on improving health and quality of life [2] - The company aims to become the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [2] Product Portfolio - Teleflex is home to several trusted brands such as Arrow™, Barrigel™, Deknatel™, QuikClot™, LMA™, Pilling™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [3] Upcoming Events - Management of Teleflex will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 3:20 p.m. (ET) [1] - A live audio webcast of the presentation will be available on the investor section of the Teleflex website [1]

Core Viewpoint - Investors in the Medical - Instruments sector should consider Teleflex (TFX) and SONOVA HOLDING (SONVY) for potential value opportunities, with TFX currently showing stronger value metrics and earnings outlook than SONVY [1][3]. Valuation Metrics - TFX has a forward P/E ratio of 8.86, significantly lower than SONVY's forward P/E of 22.79, indicating TFX may be undervalued [5]. - The PEG ratio for TFX is 1.74, while SONVY's PEG ratio is 2.23, suggesting TFX has a more favorable growth outlook relative to its valuation [5]. - TFX's P/B ratio stands at 1.3, compared to SONVY's P/B of 5.61, further highlighting TFX's superior valuation metrics [6]. Earnings Outlook - TFX holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings estimate revision trend, while SONVY has a Zacks Rank of 4 (Sell), suggesting a weaker earnings outlook [3]. - The solid earnings outlook for TFX contributes to its overall Value grade of B, while SONVY has a Value grade of C, reinforcing TFX's position as the better value option [6].

Company Overview - Teleflex Incorporated (TFX) has launched the Barrigel rectal spacer in Japan, following regulatory approval and insurance coverage acceptance, marking a significant step in its global expansion strategy [1][8] - The Barrigel rectal spacer is the first hyaluronic rectal spacer designed to protect the rectum during radiation therapy for prostate cancer, made from Non-Animal Stabilized Hyaluronic Acid [4][5] Financial Performance - Following the Barrigel launch announcement, Teleflex's shares increased by 3.7%, closing at $124.30 [2][8] - Teleflex has a market capitalization of $5.55 billion and an earnings yield of 11.3%, which is favorable compared to the industry's -5.2% [3] Product Efficacy - A clinical study in the U.S. showed that 98% of men treated with the Barrigel rectal spacer achieved at least a 25% reduction in radiation exposure to the rectum, with an average reduction of 85% in rectal V54 Gy radiation [6] Industry Prospects - Japan's prostate cancer diagnostics market generated revenues of $345.5 million in 2023 and is projected to reach $438.0 million by 2030, with a CAGR of 3.4% from 2024 to 2030 [9] - Prostate cancer was the most common cancer among men in Japan in 2022, accounting for 18% of all cancer diagnoses [9] Recent Developments - Teleflex completed the acquisition of the majority of BIOTRONIK SE & Co. KG's Vascular Intervention business for €760 million, enhancing its interventional access product line and global presence [10]

Core Viewpoint - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] Group 1: Market Performance - Since reaching a historical high on September 3, 2024, healthcare stocks have been in a "persistent downtrend," underperforming both in absolute terms and relative to the S&P 500 [1] - August is identified as a turning point for the sector, with healthcare stocks beginning to reverse their previous weak performance [1] Group 2: Economic Environment - The recovery is driven by a historically significant valuation gap and an economic backdrop characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors the healthcare sector [1] - The dual effect of valuation discount and improved sentiment provides strong justification for including healthcare stocks in investment portfolios under the current economic conditions [2] Group 3: Investment Recommendations - Evercore ISI highlights several healthcare stocks with attractive valuations and sentiment, including Cencora (COR.US), BioMarin Pharmaceutical (BMRN.US), Cigna (CI.US), Cardinal Health (CAH.US), Humana (HUM.US), Incyte (INCY.US), LabCorp (LH.US), Pfizer (PFE.US), Quest Diagnostics (DGX.US), Teleflex (TFX.US), Tenet Healthcare (THC.US), Universal Health Services (UHS.US), and Viatris (VTRS.US) [2]